| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Tongjitang Chinese Medicines Prices At $10
Posted on 03/16/2007 18:51 PM | Link | Post Comment
by Richard Daverman, PhD
Centient Biotech Investor
Tongjitang Chinese Medicines (TCM) priced its IPO at $10, down from the original target of $15-$17 and also lower than the reduced range of $12-$14. The IPO shows that the US market still has a desire to own Chinese companies. However, after the Shanghai surprise of February 27, when the Shanghai stock market lost 9% of its value in one day, US investors may not be willing to pay as high a price for that ownership.
As we reported earlier, Tongitang specializes in pill, tablet, gel or powder formulations of traditional herbal medications that the Chinese have been using for as long as one thousand years. Its lead product is Xianling Gubao, a formulation of barrenwort for osteoporosis, which comprised 77% of Tongjitang’s $62.1 million in revenue for 2006.
At $10 per ADS, Tongjitang has a market capitalization of $334 million (each ADS is equivalent to 4 ordinary shares). The company will receive net proceeds of $77.8 million from the IPO, while selling shareholders reaped $14.1 million. Mr. Xiaochun Wang, CEO and Chairman of the company, owned 56.8% of the total number of the pre-IPO shares.
A price of $10 per ADS gives Tongjitang a valuation of 5.4 times revenues and an EPS multiple of 19.5. For a company that enjoyed a CAGR of 44% in revenue and 243% in profits over the past three years, that is a bargain.
When Tongjitang was expected to net $119 million in the IPO (price=$16), it intended to spend $40 million on marketing, $10 million on research and the rest on general corporate initiatives, including, most likely, acquisitions. The remainder is now probably in the $27 million range (more if the overallotment option is exercised). Even at the lower figure, $27 million is a respectable amount of unallocated funds for a company that came into the IPO with $29 million in cash and does not have a huge budget for research.
In initial open market trading, Tongjitang is slightly lower than its IPO price. It is changing hands at $9.89, a loss of 11 cents.
Source: CentientInvestor.com
____________________
Centient Biotech Investor
Tongjitang Chinese Medicines (TCM) priced its IPO at $10, down from the original target of $15-$17 and also lower than the reduced range of $12-$14. The IPO shows that the US market still has a desire to own Chinese companies. However, after the Shanghai surprise of February 27, when the Shanghai stock market lost 9% of its value in one day, US investors may not be willing to pay as high a price for that ownership.
As we reported earlier, Tongitang specializes in pill, tablet, gel or powder formulations of traditional herbal medications that the Chinese have been using for as long as one thousand years. Its lead product is Xianling Gubao, a formulation of barrenwort for osteoporosis, which comprised 77% of Tongjitang’s $62.1 million in revenue for 2006.
At $10 per ADS, Tongjitang has a market capitalization of $334 million (each ADS is equivalent to 4 ordinary shares). The company will receive net proceeds of $77.8 million from the IPO, while selling shareholders reaped $14.1 million. Mr. Xiaochun Wang, CEO and Chairman of the company, owned 56.8% of the total number of the pre-IPO shares.
A price of $10 per ADS gives Tongjitang a valuation of 5.4 times revenues and an EPS multiple of 19.5. For a company that enjoyed a CAGR of 44% in revenue and 243% in profits over the past three years, that is a bargain.
When Tongjitang was expected to net $119 million in the IPO (price=$16), it intended to spend $40 million on marketing, $10 million on research and the rest on general corporate initiatives, including, most likely, acquisitions. The remainder is now probably in the $27 million range (more if the overallotment option is exercised). Even at the lower figure, $27 million is a respectable amount of unallocated funds for a company that came into the IPO with $29 million in cash and does not have a huge budget for research.
In initial open market trading, Tongjitang is slightly lower than its IPO price. It is changing hands at $9.89, a loss of 11 cents.
Source: CentientInvestor.com
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- e-techblog
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Millionaire Now! by Larry Nusbaum
- 360 Digest
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]
I used to make a pretty good living sharing hard won [read more]
<< My Home | TheMoneyBlogs Home